{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:37:05Z","timestamp":1783996625181,"version":"3.55.0"},"reference-count":46,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,2,14]],"date-time":"2008-02-14T00:00:00Z","timestamp":1202947200000},"content-version":"vor","delay-in-days":44,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Skinmed"],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:p> <jats:bold>\n            <jats:italic>The advent of tacrolimus at the end of the preceding century in the armamentarium of atopic dermatitis management was hailed as a breakthrough advance. It was, therefore, thought worthwhile to precisely review its origin and mechanism of action. Its topical application in the form of 0.03% to 0.1% ointments is rapidly effective and safe in pediatric and adult patients. Its use in atopic dermatitis ever since has been approved in Japan, the United States, Europe, and the Indian subcontinent. Thus, its local immunosuppressive action was fairly intriguing. Accordingly, its indications\/uses were extended to cover several inflammatory dermatoses. Vitiligo, psoriasis, alopecia areata, contact hypersensitivity, lichen planus, pyoderma gangrenosum, ichthyosis linearis circumflexa, and skin grafting\/transplant are a few unapproved indications and uses, in addition to miscellaneous dermatoses. At present, its therapeutic efficacy other then atopic dermatitis is confined to case studies, and large studies are warranted. At this point in time, therefore, it is conceivable that tacrolimus use should be carefully evaluated and used only when the conventional treatment has failed to yield favorable results. It deserves sizable caution for use in various dermatologic conditions pending its long\u2010term safety and efficacy data in large patient populations.<\/jats:italic>\n          <\/jats:bold> <\/jats:p>","DOI":"10.1111\/j.1540-9740.2007.06485.x","type":"journal-article","created":{"date-parts":[[2008,2,14]],"date-time":"2008-02-14T09:51:35Z","timestamp":1202982695000},"page":"27-30","source":"Crossref","is-referenced-by-count":35,"title":["Tacrolimus in Dermatology\u2014Pharmacokinetics, Mechanism of Action, Drug Interactions, Dosages, and Side Effects: Part I"],"prefix":"10.1111","volume":"7","author":[{"given":"Virendra N.","family":"Sehgal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govind","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Dogra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,2,14]]},"reference":[{"key":"e_1_2_8_2_2","first-page":"161","volume-title":"Drug Therapy in Dermatology","author":"Contreras Ruiz J","year":"2004"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709183371203"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.10.1203"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630500281965"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2005.03.012"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000088507"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.11.1476"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06945.x"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.44.1197"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2005.01338.x"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2005.01352.x"},{"key":"e_1_2_8_13_2","first-page":"151","article-title":"Topical tacrolimus in Hailey\u2010Hailey disease","volume":"27","author":"Rocha Paris F","year":"2005","journal-title":"Int J Tissue React"},{"key":"e_1_2_8_14_2","first-page":"223","article-title":"Cancer risk with topical pimecrolimus and tacrolimus","volume":"14","year":"2005","journal-title":"Prescrire Int"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-6-7"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.40.1256"},{"key":"e_1_2_8_17_2","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.4049\/jimmunol.139.6.1797","article-title":"Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation","volume":"139","author":"Sawada S","year":"1987","journal-title":"J Immunol"},{"key":"e_1_2_8_18_2","first-page":"74","article-title":"Tacrolimus (FK506): experience in dermatology","volume":"5","author":"Lawrence ID","year":"1998","journal-title":"Dermatologic Ther"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.04.059"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12456939"},{"key":"e_1_2_8_21_2","first-page":"491","article-title":"Topical tacrolimus (FK506): percutaneous absorption and effect on allergic and irritant contact dermatitis","volume":"110","author":"Lauerma AI","year":"1993","journal-title":"J Invest Dermatol"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000211510"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00323.x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809402800414"},{"key":"e_1_2_8_25_2","first-page":"2736","article-title":"Pharmacokinetics of FK506 in transplant patients","volume":"23","author":"Venkataramanan R","year":"1991","journal-title":"Transplant Proc"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.135.5.574"},{"key":"e_1_2_8_27_2","first-page":"468","article-title":"Topical tacrolimus treatment leads to profound alteration of the antigen presenting cells in lesions atopic dermatitis skin","volume":"107","author":"Wollenberg A","year":"1996","journal-title":"J Invest Dermatol"},{"key":"e_1_2_8_28_2","first-page":"454","article-title":"Topical FK506 suppress interleukin\u201012 and costimulatory molecular expression in vivo","volume":"109","author":"Homey B","year":"1997","journal-title":"J Invest Dermatol"},{"key":"e_1_2_8_29_2","first-page":"485","article-title":"FK506 (tacrolimus) impairs the phenotypic and functional differentiation of human epidermal Langerhans cells","volume":"107","author":"Panhans A","year":"1996","journal-title":"J Invest Dermatol"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12614216"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004030050248"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90439-5"},{"key":"e_1_2_8_33_2","first-page":"3105","article-title":"Adverse effects associated with the use of FK 506","volume":"23","author":"Fung JJ","year":"1991","journal-title":"Transplant Proc"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.8.999"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1080\/00015550310016724"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.2.229"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.4.457"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1159\/000083516"},{"key":"e_1_2_8_39_2","first-page":"237","article-title":"Tacrolimus\u2010induced tinea incognito","volume":"73","author":"Siddaiah N","year":"2004","journal-title":"Cutis"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.09.037"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06008.x"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2004.00086.x"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1159\/000095051"},{"key":"e_1_2_8_44_2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/archderm.1996.03890280081011","article-title":"Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double\u2010blind, placebo\u2010controlled study","volume":"132","author":"The European FK506 Multicentre Psoriasis Study Group","year":"1996","journal-title":"Arch Dermatol"},{"key":"e_1_2_8_45_2","first-page":"3325","article-title":"Metabolic effects of FK 506 in patient with severe psoriasis: short\u2010term follow\u2010up of seven cases","volume":"23","author":"Nikolaidis N","year":"1991","journal-title":"Transplant Proc"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)65512-2"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.2.252"}],"container-title":["SKINmed: Dermatology for the Clinician"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1540-9740.2007.06485.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1540-9740.2007.06485.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T01:39:47Z","timestamp":1697074787000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1540-9740.2007.06485.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1111\/j.1540-9740.2007.06485.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1540-9740.2007.06485.x","archive":["Portico"],"relation":{},"ISSN":["1540-9740","1751-7125"],"issn-type":[{"value":"1540-9740","type":"print"},{"value":"1751-7125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}